Search Results - "Hus, I."

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma by Giannopoulos, K, Kaminska, W, Hus, I, Dmoszynska, A

“…Background: Multiple myeloma (MM) is an immunoproliferative disease characterised by the uncontrolled proliferation of plasma cells, which is accompanied by…”
Get full text

Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations by Aapro, M, Boccia, R, Choquet, S, Hus, I, Link, H, Sliwa, T

Get full text

Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response by Hus, I, Schmitt, M, Tabarkiewicz, J, Radej, S, Wojas, K, Bojarska-Junak, A, Schmitt, A, Giannopoulos, K, Dmoszyńska, A, Roliński, J

“…Recently, we described that vaccination with allogeneic dendritic cells (DCs) pulsed with tumor cell lysate generated specific CD8+ T cell response in patients…”
Get full text

Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia by HUS, I, ROLINSKI, J, TABARKIEWICZ, J, WOJAS, K, BOJARSKA-JUNAK, A, GREINER, J, GIANNOPOULOS, K, DMOSZYNSKA, A, SCHMITT, M

“…Recently, immunotherapies with allogeneic dendritic cells (DCs) pulsed with tumor antigens to generate specific T-cell responses have been tested in clinical…”
Get full text

P692: IMMUNE FACTORS MAINTAINING TREATMENT‐FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF IMATINIB by Kwaśnik, P., Zaleska, J., Link‐Lenczowska, D., Zawada, M., Ochrem, B., Bober, G., Wasilewska, E., Mędraś, E., Hus, I., Szarejko, M., Prejzner, W., Grzybowska‐Izydorczyk, O., Klonowska‐Szymczyk, A., Sacha, T., Giannopoulos, K.

Get full text

Dendritic-Cell Tumor Vaccines by Rolinski, J, Hus, I

“…Abstract Most cancers remain incurable. Introduction of novel therapeutic methods, including new cytostatic regimens and targeted therapies, such as monoclonal…”
Get full text

The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia by Hus, I., Podhorecka, M., Bojarska-Junak, A., Roliński, J., Schmitt, M., Sieklucka, M., Wąsik-Szczepanek, E., Dmoszyńska, A.

“…Background: B-cell chronic lymphocytic leukaemia (B-CLL) is a disease with a highly variable clinical course; some patients never need treatment, while others…”
Get full text

P677: CLINICAL EFFICACY AND TOLERABILITY OF VENETOCLAX PLUS RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – REAL WORLD ANALYSIS OF POLISH ADULT LEUKEMIA STUDY GROUP by Soboń, A., Drozd‐Sokołowska, J., Paszkiewicz‐Kozik, E., Popławska, L., Morawska, M., Tryc‐Szponder, J., Bołkun, L., Rybka, J., Pruszczyk, K., Juda, A., Majeranowski, A., Iskierka‐Jażdżewska, E., Steckiewicz, P., Wdowiak, K., Budziszewska, B., Jamroziak, K., Hus, I., Lech‐Marańda, E., Puła, B.

Get full text

P1221: DIFFUSE LARGE B‐CELL LYMPHOMA RICHTER SYNDROME IN CHRONIC LYMPHOCYTIC LEUKEMIA – A RETROSPECTIVE ANALYSIS OF TREATMENT OUTCOMES IN POLISH ADULT LEUKEMIA STUDY GROUP by Sośnia, O., Danecki, M., Wąsik‐Szczepanek, E., Tryc‐Szponder, J., Iskierka‐Jażdżewska, E., Majeranowski, A., Pruszczyk, K., Krzemień, H., Bołkun, L., Paszkiewicz‐Kozik, E., Drozd‐Sokołowska, J., Kwiatkowski, J., Wiśniewska‐Organek, D., Budziszewska, B., Jamroziak, K., Hus, I., Lech‐Marańda, E., Puła, B.

Get full text

P1439: IMMUNE RESPONSE TO ANTI‐SARS‐COV‐2 MRNA VACCINES IN MULTIPLE MYELOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS by Zaleska, J., Kwaśnik, P., Paziewska, M., Purkot, J., Szabelak, A., Jurek, M., Masny, N., Dziatkiewicz, I., Własiuk, P., Skórka, K., Stasiak, G., Pronobis‐Szczylik, B., Piebiak, A., Szymczyk, A., Jarosz‐Chudzik, K., Bołkun, L., Kozłowska, K., Piszcz, J., Subocz, E., Hałka, J., Bator, M., Kalicińska, E., Wróbel, T., Usnarska‐Zubkiewicz, L., Rybka, J., Dereń‐Wagemann, I., Szyca‐Śmieszniak, M., Dybko, J., Hus, I., Puła, B., Cichocka, E., Rymko, M., Zduńczyk, D., Ziarkiewicz, M., Basak, G., Bullinger, L., Giannopoulos, K.

Get full text

Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia by GIANNOPOULOS, K, LI, L, BOJARSKA-JUNAK, A, ROLINSKI, J, DMOSZYNSKA, A, HUS, I, GREINER, J, RENNER, C, DÖHNER, H, SCHMITT, M

“…Antigen targeted immunotherapies might represent a novel treatment for B-cell chronic lymphocytic leukemia (B-CLL). We screened the mRNA expression of…”
Get full text

HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT – A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP by Hus, I., Manko, J., Jawniak, D., Jurczyszyn, A., Usnarska‐Zubkiewicz, L., Sawicki, M., Charlinski, G., Razny, M., Rodzaj, M., Waszczuk‐Gajda, A., Drozd‐Sokolowska, J., Galazka, A., Swiderska, A., Poglodek, B., Pluta, A., Druzd‐Sitek, A., Grzasko, N., Kopinska, A., Pasternak, A., Blonska, D., Hus, M., Dmoszynska, A.

Get full text

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma by HUS, I, DMOSZYNSKA, A, SULEK, K, ROBAK, T, KONOPKA, L, KLOCZKO, J, MANKO, J, HUS, M, JAWNIAK, D, SOROKA-WOJTASZKO, M, HELLMANN, A, CIEPLUCH, H, SKOTNICKI, A, WOLSKA-SMOLEN, T

“…The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM)…”
Get full text

Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma by Hus, M, Dmoszyńska, A, Kocki, J, Hus, I, Jawniak, D, Adamczyk-Cioch, M, Grzasko, N

Get full text

1813 - Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations by Aapro, M., Boccia, R., Choquet, S., Hus, I., Link, H., Sliwa, T.

Get full text

Zakażenia w przewlekłej białaczce limfocytowej – skutek czy przyczyna? by Hus, I.

Get full text

Effect of granulocyte-macrophage colony-stimulating growth factor on interferon and tumor necrosis factor production in whole blood cell cultures of patients with acute myelogenous leukemia by Kamińska, T, Hus, I, Dmoszyńska, A, Kandefer-Szerszeń, M

“…The effect of recombinat human granulocyte-macrophage colony-stimulating growth factor (rHuGM-CSF) treatment on in vitro interferon (IFN) and tumor necrosis…”
Get more information

Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts by LI LI, GIANNOPOULOS, Krzysztof, SCHMITT, Michael, REINHARDT, Peter, TABARKIEWICZ, Jacek, SCHMITT, Anita, GREINER, Jochen, ROLINSKI, Jacek, HUS, Iwona, DMOSZYNSKA, Anna, WIESNETH, Markus

“…Vaccination with dendritic cells (DCs) as professional antigen presenting cells generated from autologous leukemic blasts might elicit anti-leukemic T cell…”
Get full text

Ekspresja cząsteczki CD16 na monocytach krwi obwodowej chorych na przewlekłą białaczkę limfocytową by Bojarska-Junak, A., Hus, I., Waldowska, M., Maj, M., Tomczak, W., Hus, M., Roliński, J.

Get full text

Podwyższona ekspresja IL-10 i TGF-β w monocytach krwi obwodowej chorych na przewlekłą białaczkę limfocytową by Hus, I., Bojarska-Junak, A., Waldowska, M., Szymańska, A., Wąsik-Szczepanek, E., Tomczak, W., Hus, M., Roliński, J.

Get full text